A CBP and p300 inhibitor (IC50s 0.94 and 1.2 nM respectively) selective for CBP and p300 over BRD4 bromodomain 1 BRD4 bromodomain 2 and BRPF1 (IC50s 5.1 12 and 4.6 UM respectively) as well as nine other bromodomain-containing proteins (IC50s 18 UM for all) inhibits the expression of Myc in MV4-11 leukemia cells (EC50 6.6 nM) oral administration decreases tumor volume in a MOLM-16 AML mouse xenograft model from 3-30 mg/kg